PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.60%
Revenue growth of 1.60% while META is flat. Bruce Berkowitz would check if a small edge can widen further.
2.64%
Gross profit growth of 2.64% while META is zero. Bruce Berkowitz would see if minimal improvements could expand further.
-23.00%
Negative EBIT growth while META is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-23.00%
Negative operating income growth while META is at 0.00%. Joel Greenblatt would press for urgent turnaround measures.
-29.30%
Negative net income growth while META stands at 0.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-30.00%
Negative EPS growth while META is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-30.00%
Negative diluted EPS growth while META is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.49%
Share change of 0.49% while META is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
0.26%
Diluted share change of 0.26% while META is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-10.04%
Negative OCF growth while META is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
132.62%
FCF growth of 132.62% while META is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
13901.55%
10Y CAGR of 13901.55% while META is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
246.97%
5Y CAGR of 246.97% while META is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
61.03%
3Y CAGR of 61.03% while META is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
No Data
No Data available this quarter, please select a different quarter.
250.71%
OCF/share CAGR of 250.71% while META is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
73.60%
3Y OCF/share CAGR of 73.60% while META is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
15313.14%
10Y net income/share CAGR of 15313.14% while META is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
176.83%
Net income/share CAGR of 176.83% while META is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
33.97%
3Y net income/share CAGR of 33.97% while META is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
No Data
No Data available this quarter, please select a different quarter.
334.91%
Equity/share CAGR of 334.91% while META is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
95.48%
Equity/share CAGR of 95.48% while META is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.68%
Firm’s AR is declining while META shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
23.55%
Inventory growth of 23.55% while META is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
3.65%
Asset growth of 3.65% while META is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
5.12%
BV/share growth of 5.12% while META is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
-7.19%
We’re deleveraging while META stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
16.65%
R&D growth of 16.65% while META is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
10.68%
SG&A growth of 10.68% while META is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.